Get the Full Story, Without the Noise.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Cannes Film Festival
Eurovision
Social Media
Artificial Intelligence
Baseball
Education
European Union
Donald Trump
Property
Senate
Inflation
Mother's Day
Published • loading... • Updated

FDA clears EN-374 therapy application for X-linked chronic granulomatous disease

Summary by contemporarypediatrics.com
The in vivo hematopoietic stem cell-directed therapy received rare pediatric disease and orphan drug designations earlier this year.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
contemporarypediatrics.comcontemporarypediatrics.com

FDA clears EN-374 therapy application for X-linked chronic granulomatous disease

The in vivo hematopoietic stem cell-directed therapy received rare pediatric disease and orphan drug designations earlier this year.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

contemporarypediatrics.com broke the news in on Monday, May 12, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States

United States

News
For You
SearchBlindspotLocal